載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.405
+US$0.0986 · +32.18%
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
一般交易時段
US$0.4034
+US$0.097 · +31.66%
盤中時間採用ET。市場資料可能有所延遲。
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
日內區間
目前US$0.4034
52週區間
目前US$0.4034
盤中時間採用ET。市場資料可能有所延遲。
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
日內區間
目前US$0.4034
52週區間
目前US$0.4034
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 33.2萬 USD | 54.5萬 USD | 83.5萬 USD | 77.7萬 USD | 54.6萬 USD |
| 毛利 | −33.2萬 USD | −54.5萬 USD | −83.5萬 USD | −77.7萬 USD | −54.6萬 USD |
| 研究與開發 | 892.2萬 USD | 1012.6萬 USD | 1923.5萬 USD | 1869.3萬 USD | 1288.1萬 USD |
| 銷售、一般及管理費用 | 568.5萬 USD | 491.3萬 USD | 613.9萬 USD | 670.2萬 USD | 624萬 USD |
| 營業費用 | 1466.8萬 USD | 1499.1萬 USD | 2939.5萬 USD | 2579.7萬 USD | 1928.8萬 USD |
| 利息收入 | 79.2萬 USD | 106.9萬 USD | 156.5萬 USD | 83.5萬 USD | 12萬 USD |
| 利息支出 | 1.3萬 USD | 1.3萬 USD | 1.4萬 USD | 526.3萬 USD | 32.8萬 USD |
| 折舊和攤銷 | 33.2萬 USD | 54.5萬 USD | 83.5萬 USD | 77.7萬 USD | 54.6萬 USD |
| 營業利益 | −1500萬 USD | −1553.6萬 USD | −2939.5萬 USD | −2579.7萬 USD | −1928.8萬 USD |
| 淨利 | 12.36億 USD | −1501.4萬 USD | −2906.8萬 USD | −3106萬 USD | −1446.8萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$15.00
上漲空間 3618.39%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年7月9日 | 1:15 | — | — |
股票分割 | 2019年3月6日 | 1:8 | — | — |
股票分割 | 2017年9月25日 | 1:5 | — | — |
已生效 2026年7月9日
1:15
已生效 2019年3月6日
1:8
已生效 2017年9月25日
1:5
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
